Back to results
US 2003/0166550 A1Published application
Angiogenically effective unit dose of FGF-2 and method of use
AssigneeChiron Corporation
InventorMartha Jo Whitehouse
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeChiron Corporation
InventorMartha Jo Whitehouse
Estimating the term…
The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts six months before retreatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.
A unit dose composition for inducing angiogenesis in a human, comprising about 0.008 mg to about 7.2 mg of FGF-2 or an angiogenically active fragment or an angiogenically active mutein thereof in a pharmaceutically acceptable carrier.
A unit dose composition for inducing angiogenesis in a human, comprising about 0.008 mg to about 7.2 mg of FGF-2 in a pharmaceutically acceptable carrier, wherein said FGF-2 has the sequence set forth in SEQ ID NO:2.
The unit dose composition of claim 11, comprising 0.3 mg to 3.5 mg of said FGF-2 in a pharmaceutically acceptable carrier.
A unit dose composition for inducing angiogenesis in a human, comprising about 0.008 mg to about 7.2 mg of an angiogenically active fragment of FGF-2 or an angiogenically active mutein of FGF-2, wherein said FGF-2 has the sequence set forth in SEQ ID NO:2.
Dependencies are inferred from the claim text.